美国 · SEC FORM 4
Alamar Biosciences, Inc.
ALMR · Nasdaq · CIK 0002104204 · Healthcare · Medical Devices
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
2 同一窗口内观察到的 Form 4 交易行
0 sales · 2 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-04-20 · Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas · $4.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Brottem John L.General Counsel
○
RAGUSA ROBERT PDirector
○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
61.1 / 100
最新留档分数
→ +0.0 pts相对上一个留档快照
- 61.1
- 61.1
- 61.1
- 61.1
- 61.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
2买入
0卖出
44其他 Form 4 交易行
9SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他2 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -9.0%
- 3M
- -7.8%
- 6M
- —
- 12M
- —
波动率与流动性
- 波动率
- 86.0%
- Beta
- —
- 平均每日成交额
- USD 10.7M
估值
- 市值
- USD 1.8B
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Medical Devices
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,810,938
- 上期报告
- 2,122,340
- 日均成交量
- 661,422
- 回补天数
- 4.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-20 | Naclerio Nicholas | 买入 (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | 买入 (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC 申报 ↗ |
Form 4 申报证据
46 transaction lines in the latest 365-day window; 46 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Brottem John L. | 奖励／授予 (A) | Common Stock | 29,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-01 | RAGUSA ROBERT P | 奖励／授予 (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Common Stock | 10,594,547 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (28 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Brottem John L. | 奖励／授予 (A) | Common Stock | 29,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-01 | RAGUSA ROBERT P | 奖励／授予 (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Common Stock | 10,594,547 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | J (J) | Class B Common Stock | 10,594,547 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd.; Qiming GP VIII, LLC; Qiming GP VIII-HC, LLC; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming Venture Partners VIII Investments, LLC; Qiming Venture Partners VIII-HC, L.P. | C (C) | Class B Common Stock | 10,594,547 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | White Timothy Ogden | J (J) | Common Stock | 454,583 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | White Timothy Ogden | J (J) | Class B Common Stock | 454,583 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | White Timothy Ogden | 奖励／授予 (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | 买入 (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | J (J) | Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | J (J) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | C (C) | Common Stock | 617,802 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | C (C) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Naclerio Nicholas | 奖励／授予 (A) | Common Stock | 5,686 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | McAnear Justin J. | 奖励／授予 (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Luo Yuling | J (J) | Common Stock | 3,088,217 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Luo Yuling | J (J) | Class B Common Stock | 3,088,217 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Luo Yuling | C (C) | Class B Common Stock | 2,975,166 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Luo Yuling | 奖励／授予 (A) | Common Stock | 76,509 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | 买入 (P) | Common Stock | 235,294 | USD 17.00 | USD 3,999,998 | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | J (J) | Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | J (J) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | C (C) | Common Stock | 617,802 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C.; Illumina Innovation Fund II, L.P.; Illumina Innovation Fund III GP, L.L.C.; Illumina Innovation Fund III, L.P.; Naclerio Nicholas | C (C) | Class B Common Stock | 5,510,516 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Chen Shiping | J (J) | Common Stock | 722,885 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Chen Shiping | J (J) | Class B Common Stock | 722,885 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Chen Shiping | C (C) | Class B Common Stock | 393,364 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-20 | Chen Shiping | 奖励／授予 (A) | Common Stock | 37,220 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ALMR |
| CIK | 0002104204 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3826 Laboratory Analytical Instruments |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 46 transaction lines from 2026-04-20 to 2026-09-14 2 P purchase lines · 0 S sale lines · 44 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.